Empower Pharmacy: What It Is and Who It Supplies

Empower is one of the handful of compounding operations whose name a patient is likely to meet twice: once on a telehealth company's pharmacy disclosure, and once in a headline. It is unusual in this market because it runs two regulated businesses at the same time, under two different rulebooks, from two different buildings in Houston. Knowing which of the two filled your vial changes what standard that vial was made to. Checked August 29, 2026.

Two businesses, two rulebooks

Empower's own homepage describes the company as the "nation's premier 503A compounding pharmacy and 503B outsourcing facility"¹, and its about page lists the two credentials separately: a "PCAB Accredited 503A Compounding Pharmacy" and an "FDA Registered 503B Outsourcing Facility"². Those are not two labels for one thing. They are two categories of compounder that federal law treats differently.

Empower's own facilities page draws the line the same way the statute does: "Our 503A pharmacy provides patient-specific compounding services," while "Our 503B outsourcing facility serves practices and institutions, and other pharmacies with office-use medications"³. The company says it has invested "more than $55 million in purpose-built compounding and manufacturing facilities"² and operates "210,000 square feet of outsourcing facilities" that run "under cGMP, and is subject to federal inspection"³.

The FDA states the underlying difference in a sentence worth keeping: "Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not"⁸. A 503B facility is inspected by the FDA on a risk-based schedule; a 503A pharmacy is supervised day to day by its state board of pharmacy. Neither route produces an FDA-approved drug. As the agency puts it: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"⁸.

Which side of the house makes the GLP-1

This is the part most write-ups get wrong, and Empower answers it on its own product page. Its semaglutide preparation "is available exclusively through our 503A compounding pharmacy pursuant to a patient-specific prescription"⁴. The same page carries the disclosure in plain words: "Compounded medications, such as Semaglutide/Cyanocobalamin, are not FDA-approved medications, and FDA does not review compounded medications for safety or efficacy"⁴.

So the 503B side — the cGMP side, the FDA-inspected side, the one the marketing leans on — is not the side that fills a weight-loss prescription for an individual patient. That work sits in the 503A pharmacy, which is regulated by Texas, not by the FDA's manufacturing rules. If a company's pharmacy disclosure says only "Empower," it has told you the company and not the standard.

What FDA's own records show

The FDA publishes a weekly table of every facility registered as an outsourcing facility under section 503B. On the version read August 29, 2026, that table listed 98 facilities, two of them under Empower's ownership: "Empower Pharma, Houston, TX," initially registered July 16, 2016 and most recently November 24, 2025, and "Empower Clinic Services New Jersey, East Windsor, NJ," initially registered June 10, 2024⁵.

The same row for the Houston facility records a most recent inspection of November 14, 2025, a Form FDA 483 issued, and an "Action Based on Last Inspection" of "Open." The FDA defines both terms on the page. A Form 483 "is issued when investigators observe any significant objectionable conditions. It does not constitute a final agency determination of whether any condition is in violation of the FD&C Act or any relevant regulations." And "'Open' means FDA has not determined whether further action will be taken"⁵. Neither is a verdict; both are facts a reader is entitled to.

Empower has also received three FDA warning letters, and all three are open. Two were issued on April 2, 2025, to the two Houston addresses, and the agency classifies both under the subject "Compounding Pharmacy/Adulterated Drug Products." One is addressed to "Empower Clinic Services, LLC dba Empower Pharma" at 5980 West Sam Houston Parkway North, Suite 300, the 503B facility⁶; the other to "Empower Clinic Services, LLC dba Empower Pharmacy" at 7601 N Sam Houston Pkwy W Ste 100, the 503A pharmacy⁷. A third and earlier letter went to "Empower Clinic Services, LLC dba Empower Pharmacy" at 5980 West Sam Houston Parkway North, Suite 300 on October 15, 2021, from a different FDA office⁹ — the same address as the 2025 Empower Pharma letter but a different trade name, which is exactly why the entity name alone will not find these. Those entity names and addresses are how you find the documents in FDA's database, which is the reason to print them.

A warning letter is a disclosure, not a disqualification, and we do not restate what is in one. Read the letters themselves if the question matters to you; the entity name and the date are all you need to find them.

Who dispenses through Empower

Two of the 507 companies tracked on this site name Empower. One is Empower's own entry — the pharmacy is listed here in its own right, at Empower Pharmacy. The other is Pomegranate Health, whose public pricing page names six compounding pharmacies behind its products, Empower among them. That is a fact about our record, not about Empower's customer list: the company says it serves "patients, practitioners, and pharmacies"² and is "licensed to ship nationwide, including Puerto Rico"¹, and a telehealth company that does not publish its pharmacy would not show up in a count like this one. The absence tells you where to look next, not what to conclude.

Checking a compounding pharmacy yourself

Four checks, in order, and none of them takes long. First, ask which pharmacy fills the prescription and get the answer in writing — a company that will not name it has ended the conversation for you. Second, look the name up in FDA's registered outsourcing facilities table; if it is there, the facility is on FDA's inspection schedule and the table shows the last inspection date and whether a Form 483 was issued. Third, if it is not there, that is not a strike — most compounding pharmacies are 503A and belong to their state board of pharmacy instead, so search your own state board's license lookup for a nonresident pharmacy license. Fourth, search FDA's warning-letter database on the legal entity name rather than the trading name, because letters are addressed to companies, not to brands.

The other pharmacies named most often by companies on this ranking each have their own page: Hallandale, Red Rock and Olympia. The wider question of who is allowed to compound what is covered in is compounded GLP-1 legit and safe, the checks that separate a licensed operator from a storefront are in how to tell if a GLP-1 provider is legit, coverage by state is at GLP-1 telehealth by state, and the sources behind these pages are indexed in our research library.